Reviewing TriSalus Life Sciences (NASDAQ:TLSI) & InspireMD (NYSE:NSPR)

TriSalus Life Sciences (NASDAQ:TLSI) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for TriSalus Life Sciences and InspireMD, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	0	0	N/A
InspireMD	0	0	1	0	3.00

InspireMD has a consensus target price of $4.85, indicating a potential upside of 129.86%. Given InspireMD’s higher possible upside, analysts plainly believe InspireMD is more favorable than TriSalus Life Sciences.

Risk & Volatility

TriSalus Life Sciences has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Valuation and Earnings

This table compares TriSalus Life Sciences and InspireMD’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$18.51 million	13.96	-$59.04 million	N/A	N/A
InspireMD	$6.21 million	7.96	-$19.92 million	($1.08)	-1.95

InspireMD has lower revenue, but higher earnings than TriSalus Life Sciences.

Profitability

This table compares TriSalus Life Sciences and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	N/A	N/A	-166.18%
InspireMD	-320.97%	-55.71%	-46.53%

Insider and Institutional Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by insiders. Comparatively, 29.7% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

InspireMD beats TriSalus Life Sciences on 6 of the 11 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.